Compare MSI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSI | CANF |
|---|---|---|
| Founded | 1928 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.3B | 5.0M |
| IPO Year | N/A | N/A |
| Metric | MSI | CANF |
|---|---|---|
| Price | $364.29 | $0.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $502.50 | $6.75 |
| AVG Volume (30 Days) | 1.6M | ★ 19.6M |
| Earning Date | 10-30-2025 | 11-27-2025 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 36.31 | N/A |
| EPS | ★ 12.46 | N/A |
| Revenue | ★ $11,313,000,000.00 | $560,000.00 |
| Revenue This Year | $8.75 | $461.72 |
| Revenue Next Year | $8.25 | N/A |
| P/E Ratio | $29.27 | ★ N/A |
| Revenue Growth | ★ 6.18 | N/A |
| 52 Week Low | $363.37 | $0.28 |
| 52 Week High | $492.22 | $2.33 |
| Indicator | MSI | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 25.74 | 31.65 |
| Support Level | $369.05 | $0.31 |
| Resistance Level | $376.03 | $0.33 |
| Average True Range (ATR) | 6.26 | 0.03 |
| MACD | 1.81 | 0.00 |
| Stochastic Oscillator | 1.74 | 0.71 |
Motorola Solutions is a leading provider of communications and analytics, primarily serving public safety departments as well as schools, hospitals, and businesses. The bulk of the firm's revenue comes from sales of land mobile radios and radio network infrastructure, but the firm also sells surveillance equipment, dispatch software, and other networking capabilities. Most of Motorola's revenue comes from government agencies, while roughly 25% comes from schools and private businesses. Motorola has customers in over 100 countries and in every state in the United States.
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).